These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 33021345)

  • 1. Creating an environment for equitable access to direct-acting antiviral therapy for people who inject drugs with hepatitis C.
    Dore GJ; Valerio H; Grebely J
    Liver Int; 2020 Oct; 40(10):2353-2355. PubMed ID: 33021345
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug-drug interactions with direct-acting antivirals - less is more.
    Wong GL
    Clin Mol Hepatol; 2021 Jan; 27(1):81-82. PubMed ID: 33317241
    [No Abstract]   [Full Text] [Related]  

  • 3. It's Not Them, It's Us: Hepatitis C Reinfection Following Successful Treatment Among People Who Inject Drugs.
    Barocas JA
    Clin Infect Dis; 2021 Apr; 72(8):1401-1403. PubMed ID: 32166311
    [No Abstract]   [Full Text] [Related]  

  • 4. Personal, provider and system level barriers and enablers for hepatitis C treatment in the era of direct-acting antivirals: Experiences of patients who inject drugs accessing treatment in general practice settings in Australia.
    Heard E; Smirnov A; Massi L; Selvey LA
    J Subst Abuse Treat; 2021 Aug; 127():108460. PubMed ID: 34134878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patient-reported outcomes of the Treatment and Prevention Study: A real-world community-based trial of direct-acting antivirals for hepatitis C among people who inject drugs.
    Goutzamanis S; Spelman T; Harney B; Dietze P; Stoove M; Higgs P; Thompson A; Doyle JS; Hellard M
    J Viral Hepat; 2021 Jul; 28(7):1068-1077. PubMed ID: 33880820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure?
    Asselah T; Marcellin P; Schinazi RF
    Liver Int; 2018 Feb; 38 Suppl 1(Suppl 1):7-13. PubMed ID: 29427484
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Is resistance to direct-acting antivirals in sub-Saharan Africa a threat to HCV elimination? Recommendations for action.
    Gupta N; Kateera F; Desalegn H; Ocama P; Njouom R; Lacombe K
    J Hepatol; 2020 Mar; 72(3):583-584. PubMed ID: 31836263
    [No Abstract]   [Full Text] [Related]  

  • 8. Patient Centeredness in Hepatitis C Direct-Acting Antiviral Treatment Delivery to People Who Inject Drugs: A Scoping Review.
    Abdelwadoud M; Mattingly TJ; Seguí HA; Gorman EF; Perfetto EM
    Patient; 2021 Sep; 14(5):471-484. PubMed ID: 33372245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years.
    Dennis BB; Naji L; Jajarmi Y; Ahmed A; Kim D
    World J Gastroenterol; 2021 Aug; 27(29):4818-4830. PubMed ID: 34447228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effectiveness and safety of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection].
    Yang J; Rao HY
    Zhonghua Gan Zang Bing Za Zhi; 2018 Mar; 26(3):175-178. PubMed ID: 29804389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Call to Action: HCV Treatment of People Who Inject Drugs in the United States.
    Norton BL; Litwin AH
    Clin Infect Dis; 2020 May; 70(11):2366-2368. PubMed ID: 31513706
    [No Abstract]   [Full Text] [Related]  

  • 12. [Therapeutic update in hepatitis C].
    Devesa MJ; Cuenca F; Izquierdo S; Sánchez-Pobre P; Ladero JM; López-Alonso G; Díaz-Rubio M; Rey E
    Rev Esp Quimioter; 2015 Sep; 28 Suppl 1():48-51. PubMed ID: 26365735
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Feasibility and acceptability of adherence support for direct acting antiviral therapy for hepatitis C in a low-threshold primary health-care opioid agonist treatment program.
    Chronister KJ; Lothian R; Gilliver R; Kearley J; Read P
    Drug Alcohol Rev; 2019 Feb; 38(2):185-189. PubMed ID: 30761640
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Chronic Hepatitis C in Patients Receiving Opioid Agonist Therapy: A Review of Best Practice.
    Norton BL; Akiyama MJ; Zamor PJ; Litwin AH
    Infect Dis Clin North Am; 2018 Jun; 32(2):347-370. PubMed ID: 29778260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C Virus Reinfection Rate Among Persons Who Use Drugs and Are Maintained on Medication Treatment for Opioid Use Disorder.
    Springer SA
    Clin Infect Dis; 2020 Jun; 70(12):2703-2705. PubMed ID: 31346595
    [No Abstract]   [Full Text] [Related]  

  • 16. [Price analyses on direct-acting antiviral drugs of hepatitis C].
    Duan CAX; Sui BY; Chen ZD; Zhao K
    Zhonghua Yu Fang Yi Xue Za Zhi; 2020 Oct; 54(10):1161-1164. PubMed ID: 33115205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telemedicine, time to change the paradigm of hepatitis C management: improve access and reduce costs In reference to: Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience, by Pérez Hernández et al.
    Cabezas J; Llerena S; Crespo J
    Rev Esp Enferm Dig; 2021 Aug; 113(8):623-624. PubMed ID: 33569962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Antiviral therapy of chronic hepatitis C: 30 years success story].
    Abdurakhmanov DT; Rozina TP; Nikulkina EN; Burnevich EZ; Tanashuk EL; Severov MV; Filatova AL; Milovanova SY; Karpov VV; Moiseev SV
    Ter Arkh; 2019 Nov; 91(11):110-115. PubMed ID: 32598621
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiviral drugs have made hepatitis C eminently treatable.
    Ladika S
    Manag Care; 2018 Nov; 27(11):23-30. PubMed ID: 30620304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A National Hepatitis C Elimination Program in the United States: A Historic Opportunity.
    Fleurence RL; Collins FS
    JAMA; 2023 Apr; 329(15):1251-1252. PubMed ID: 36892976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.